Skip to content

AACR Annual Meeting 2026

April 17–22, 2026 · San Diego · 2418 items

Over 22,000 attendees and more than 7,400 abstracts, including a record 265 clinical trial abstracts. This section collects on-site analysis across fifteen signal directions, plus late-breaking, clinical-trial and new-drug abstracts.

NO.01↓ 17%
Participants counted12
Heat, past 24h
24h agonow
and 12 other sources reporting·12 participants
36
Heat index
NO.03↓ 29%

nivolumab

4 sources · 4 participants
15

Page 1 No.04–20

  1. 04

    daraxonrasibBuilding

    14↑ 97%
  2. 05

    #EARLYCAREER

    13↓ 29%
  3. 06

    #LCSMBuilding

    11↑ 203%
  4. 07

    pembrolizumab

    8↓ 29%
  5. 08

    #GYNCSM

    8↓ 30%
  6. 09
  7. 10

    HER2

    7↓ 29%
  8. 11

    adebrelimab

    7↓ 29%
  9. 12

    #MYELOMA

    2↓ 30%
  10. 13
  11. 14
  12. 15
  13. 16

    #CANCERDATA

    6↓ 29%
  14. 17

    MET

    5↓ 29%
  15. 18

    zanidatamab

    5↓ 30%
  16. 19

    #NSCLC

    4↓ 30%
  17. 20

    KEAP1

    4↓ 29%
CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org